On November 12, Health100 will release this news: CSPC Innovation Pharmaceutical (300765.SZ) announced that its subsidiary, CSPC Pharma, received the Drug Clinical Trial Approval Notice for the therapeutic vaccine SYS6026 for relevant precancerous lesions caused by human papillomavirus (HPV) issued by the National Medical Products Administration, and will start clinical trials soon.

SYS6026 is the first therapeutic vaccine developed independently based on the company's mRNA platform, consisting of messenger RNA (mRNA) molecules combined with lipid nanoparticle (LNP) delivery system. This product induces a specific T cell immune response by expressing HPV16 or 18 type E6 and E7 antigens through mRNA, thereby clearing HPV-infected cells and blocking the carcinogenesis process.

Current clinical treatment methods mainly rely on surgery, which has the disadvantages of causing great harm to patients and being prone to recurrence. As an efficient non-surgical treatment option, this product is expected to address significant clinical needs in this field and has high clinical development value. So far, there is no HPV therapeutic vaccine available globally.

The approved clinical indication for this treatment is for human papillomavirus (HPV) 16/18-related high-grade squamous intraepithelial lesion (HSIL).